>

Orphazyme Stock Performance

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>OR</div>
ORPHA -- Denmark Stock  

DKK 90.70  0.10  0.11%

On a scale of 0 to 100 Orphazyme holds performance score of 4. The organization holds a Beta of -0.027, which implies as returns on market increase, returns on owning Orphazyme are expected to decrease at a much smaller rate. During bear market, Orphazyme is likely to outperform the market. Although it is vital to follow to Orphazyme AS current trending patterns, it is good to be conservative about what you can actually do with the information regarding equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing Orphazyme AS technical indicators you can presently evaluate if the expected return of 0.4385% will be sustainable into the future. Please employ Orphazyme AS Treynor Ratio as well as the relationship between Potential Upside and Expected Short fall to make a quick decision on weather Orphazyme historical price patterns will revert.
View Stock Performance For
Refresh
44

Orphazyme Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Orphazyme AS are ranked lower than 4 (%) of all global equities and portfolios over the last 30 days. Despite somewhat conflicting basic indicators, Orphazyme sustained solid returns over the last few months and may actually be approaching a breakup point.
Quick Ratio2.04
Fifty Two Week Low47.60
Target High Price135.00
Fifty Two Week High137.50
Target Low Price107.00

Orphazyme Relative Risk vs. Return Landscape

If you would invest  8,000  in Orphazyme AS on March 5, 2020 and sell it today you would earn a total of  1,080  from holding Orphazyme AS or generate 13.5% return on investment over 30 days. Orphazyme AS is generating 0.4385% of daily returns and assumes 6.541% volatility on return distribution over the 30 days horizon. Simply put, 58% of equities are less volatile than Orphazyme and 92% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
    
  Risk (%) 
Assuming 30 trading days horizon, Orphazyme is expected to generate 1.7 times more return on investment than the market. However, the company is 1.7 times more volatile than its market benchmark. It trades about 0.07 of its potential returns per unit of risk. The DOW is currently generating roughly -0.11 per unit of risk.

Orphazyme Market Risk Analysis

Sharpe Ratio = 0.067
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsORPHA
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns

Orphazyme Stock Performance Indicators

Estimated Market Risk
 6.54
  actual daily
 
 58 %
of total potential
 
5858
Expected Return
 0.44
  actual daily
 
 8 %
of total potential
 
88
Risk-Adjusted Return
 0.07
  actual daily
 
 4 %
of total potential
 
44
Based on monthly moving average Orphazyme is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orphazyme by adding it to a well-diversified portfolio.

Orphazyme Alerts

Equity Alerts and Improvement Suggestions

Orphazyme AS has very high historical volatility over the last 30 days
Orphazyme AS has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
Net Loss for the year was (337.5 M).
The company has accumulated about 123.59 M in cash with (326.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57.
Please check Your Equity Center. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page